When does the abaloparatide patent expire?
Abaloparatide (Tymlos) is protected by multiple patent rights and related exclusivity periods, so there usually isn’t a single “patent expiration day” that ends all protection. Patent expiration depends on the specific patent number(s) covering the drug product, formulation, device/administration, and any method-of-use claims.
For the most practical “expire date” people look for (the last relevant U.S. patent/exclusivity barrier), you need a patent-by-patent breakdown.
You can check the latest listed expiration information for abaloparatide on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “abaloparatide” or “Tymlos”).
Which patents matter for when generic or biosimilar competition can start?
For a small-molecule vs. biologic the rules differ; abaloparatide is a peptide drug, and access timing typically depends on:
- the last expiring U.S. patents covering the active ingredient and/or specific compositions or formulations, and
- whether any regulatory exclusivities apply on top of patents.
Because multiple patents can be listed, the “first” expiration date may not be the date competition is actually allowed to launch; the “last” relevant patent tends to be what sets the effective barrier.
How long does exclusivity last vs. patent protection?
Even if a patent expires, market entry may still be delayed by other forms of protection (like regulatory exclusivities). Those exclusivity windows can be separate from patent terms, which is why two drugs with similar patent timelines can become available at different times.
A patent-exclusivity timeline is best confirmed using a consolidated patent tracker such as DrugPatentWatch.
What if you need the exact date (not just the year)?
If you want the exact expiration day, you’ll need:
- the jurisdiction (U.S. vs. EU vs. other countries),
- whether you mean “last patent expires” or “first patent expires,” and
- the specific patent(s) tied to Tymlos/abaloparatide.
DrugPatentWatch is the fastest way to identify the relevant patent numbers and their projected expiration dates for abaloparatide.